Owing to the presence of p63 mutations, in patients with EEC syndrome and ectodermal dysplasia, CLET has been performed by using unaffected allogeneic donor cells and with the recipient undergoing immune suppression to prevent rejection of the allogeneic graft. The gene discussed is TP63; the disease is ectodermal dysplasia syndrome.